Journal profile · Biochemistry, Genetics and Molecular Biology-Biochemistry, Genetics and Molecular Biology (all)
Journal of Advanced Biotechnology and Experimental Therapeutics
ISSN 2616-4760 · Bangladesh Society for Microbiology, Immunology and Advanced Biotechnology · Bangladesh
Journal of Advanced Biotechnology and Experimental Therapeutics: fully open access; APC about USD 469; review about 30 days (submission to final decision, publisher); acceptance rate 12% (journal website); 41 articles in 2025; indexed in Scopus.
Scope
Aims, scope and focus
Journal of Advanced Biotechnology and Experimental Therapeutics is published by Bangladesh Society for Microbiology, Immunology and Advanced Biotechnology. By OpenAlex counts of its recent articles, its largest topics are Medicinal Plant Research, Antibiotic Resistance in Bacteria and SARS-CoV-2 and COVID-19 Research, together about 28.3% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
JABET is a peer-reviewed journal devoted to publishing the latest developments in translational research and recent discoveries in the field of Biotechnology and Biomedical Sciences. JABET provides a platform for scientists and academicians all over the world to promote, share, and discuss various new issues in the biotechnology and biomedical sciences.
From the journal's Aims & Scope
Research area (LetPub): Biochemistry, Genetics and Molecular Biology-Biochemistry, Genetics and Molecular Biology (all)
Main research topics OpenAlex counts of recent articles; shares are approximate
- Medicinal Plant ResearchAgricultural and Biological Sciences16%
- Antibiotic Resistance in BacteriaBiochemistry, Genetics and Molecular Biology7.2%
- SARS-CoV-2 and COVID-19 ResearchMedicine5.2%
- Sperm and Testicular FunctionMedicine4.6%
- Animal Nutrition and PhysiologyAgricultural and Biological Sciences4.6%
- Essential Oils and Antimicrobial ActivityAgricultural and Biological Sciences4.6%
- COVID-19 Clinical Research StudiesMedicine4.2%
- Natural Antidiabetic Agents StudiesMedicine4.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Not covered
Not covered by this edition.
CAS Xinrui Journal Ranking (March 2026)Not covered
Not covered by this edition.
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
CiteScore quartiles (Scopus, June 2026 release)
| Subject | Quartile | Rank | Percentile |
|---|---|---|---|
| Plant Science | Q3 | 301/541 | 44th |
| General Biochemistry, Genetics and Molecular Biology | Q3 | 143/223 | 36th |
| Applied Microbiology and Biotechnology | Q3 | 96/134 | 28th |
Scopus ranks journals by CiteScore within each subject: the 75th percentile and above is Q1, then a quartile every 25 points. A different system from the CAS zones.LetPub
Database indexing
ScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- CiteScore 2026-06
- 2.1LetPub ·
- CiteScore (publisher)
- 2.5Publisher website ·
- SJR 2026-06
- 0.23LetPub ·
- SNIP 2026-06
- 0.34LetPub ·
- h-index
- 17OpenAlex ·
- i10-index
- 48OpenAlex ·
- 2-year mean citedness
- 1.03OpenAlex ·
- Share of gold OA articles
- 0%LetPub ·
Articles by year OpenAlex count · 389 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 42 | 42 | 276 |
| 2025 | 41 | 41 | 323 |
| 2024 | 51 | 51 | 342 |
| 2023 | 49 | 49 | 246 |
| 2022 | 68 | 68 | 182 |
| 2021 | 42 | 42 | 127 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Publisher-reported review time from the journal's website
30 dayssubmission to final decision · community reports about 8 weeks
The publisher's own definition applies; dates from this journal's articles in the last 24 months are not available yet, so the publisher's figure is used.
Figures by source
- Average review time (community reports)
- about 8 weeksLetPub ·
- Acceptance rate (publisher)
- 12%Publisher website ·
- Submission to final decision
- 30 daysPublisher website ·
- Acceptance to publication
- 7 daysPublisher website ·
- Submission to publication (journal-reported)
- about 7 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 469 | Yes | CC BY | |
| OpenAlex | USD 169 | — | — | |
| Publisher website | USD 469 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted3
- original articleOriginal article Age and associated factors affecting the survival rate of ovarian cancer patientsLength not stated
- review articleReview article AI-assisted and structure-based small-molecule aptamer discovery: From SELEX to validationLength not stated
- short communicationShort communication Effects of andrographolide on p53 and Ki67 expression in an experimental mouse model of endometriosisLength not stated
Policy excerpts from the journal's websitePublication ethics
- Publication ethics Publication ethics
JABET follows the rules and regulations set by ICMJE (The International Committee of Medical Journal Editors). So, the authors are requested to prepare their manuscripts accordingly for publication.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Bangladesh Society for Microbiology, Immunology and Advanced Biotechnology
- Country or region
- Bangladesh
- Language
- English
- ISSN
- 2616-4760
- Official links
- Journal homepage ↗LetPub
- Submission system ↗Publisher website
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Journal of Advanced Biotechnology and Experimental Therapeutics
How long does peer review take at Journal of Advanced Biotechnology and Experimental Therapeutics?
The publisher reports about 30 days (submission to final decision); authors report an average review time of about 8 weeks; the journal's website gives an acceptance rate of 12%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Journal of Advanced Biotechnology and Experimental Therapeutics?
According to LetPub and DOAJ records, Journal of Advanced Biotechnology and Experimental Therapeutics is indexed in Scopus and DOAJ.
Is Journal of Advanced Biotechnology and Experimental Therapeutics open access, and what is the APC?
Journal of Advanced Biotechnology and Experimental Therapeutics is a fully open-access journal. APC about USD 469.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .